Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Carmot Therapeutics, Inc.
With
Hoffmann-La Roche
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, 18 to 75 years of age
Body mass index (BMI) ≥30.0 kg/m2, OR BMI ≥27.0 and \<30.0 kg/m2 and previously diagnosed with at least 1 of the following weight-related comorbidities, such as: prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
At least one self-reported unsuccessful effort to lose body weight
You may not be if
Prior history/diagnosis/lab evidence of any type of diabetes mellitus (e.g., Type 1, Type 2, gestational), or a history of ketoacidosis or hyperosmolar state
Self-reported body weight change of \>5 kg within 3 months before randomization
Any unbalanced/extreme diets within 3 months of the screening visit, or plan to be on such diets during the study
Current or recent participation in an organized weight reduction program
Current or recent use of any treatment that promotes weight loss or glucose metabolism
Current or recent use of treatment that may cause weight gain
Prior or planned surgical treatment for obesity
Clinically significant or active gastric emptying abnormality, malabsorption, or chronic use of medications that directly affect GI motility
History of chronic pancreatitis or acute pancreatitis within 6 months before screening
Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity
History of major depressive disorder within 2 years of screening, or any history/diagnosis of other severe psychiatric conditions (Note: Prospective participants with depression or anxiety whose disease state, in the opinion of the Investigator, is considered stable and expected to remain stable throughout the course of the study, may be considered for inclusion)
Family or personal history of medullary thyroid carcinoma
Serum calcitonin ≥ 20 ng/L
Women who are pregnant, breastfeeding, or intend to become pregnant, or are of childbearing potential and not using a highly effective contraceptive method
Clareo Health | A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
